Acorda Therapeutics (ACOR) Misses Q4 EPS by 6c, Sales Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2016
February 14, 2017 6:00 AM ESTAMPYRA® (dalfampridine) 4Q 2016 Net Revenue of $132 Million; Full-Year Net Revenue of $493 Million AMPYRA 2017 Net Sales Guidance of $535-$545 Million Positive CVT-301 Phase 3 Data Support 2Q 2017 NDA Filing
ARDSLEY, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, Inc. (Nasdaq: ACOR) today provided a financial and pipeline update for the fourth quarter and full... More
